Human Cathelicidin LL-37 - Does It Influence the Homeostatic Imbalance in Mental Disorders?

Overview

Journal J Biosci

Specialties Biochemistry
Biology

Date 2018 Jun 7

PMID 29872020

Citations 2

Authors

Elzbieta Kozlowska

Adam Wysokinski

Karol Majewski

Justyna Agier

Aleksandra Margulska

Ewa Brzezinska-Blaszczyk

Affiliations

Soon will be listed here.

Abstract

In addition to killing pathogens and influencing immunological processes, cathelicidin LL-37 is a multifunctional host defense peptide with a role in homeostasis. It has been suggested that imbalances in homeostatic signaling from inflammatory/ immune, endocrine and metabolic cascades and oxidative stress may partially contribute to the pathogenesis of mental disorders. The purpose of the study was to identify any differences in LL-37 levels between patients with schizophrenia, euthymic bipolar disorder, bacterial pneumonia, pulmonary tuberculosis, and healthy controls. Thirty-five patients with chronic paranoid schizophrenia, 40 patients with chronic, euthymic bipolar disorder, 30 patients with bacterial pneumonia, 32 patients with pulmonary tuberculosis, and 38 healthy volunteers were included in this study. The patients with schizophrenia demonstrated a significantly lower level of LL-37 than those with bipolar disorder (p=0.006) and those with pulmonary TB (p less than 0.001). Significant differences in LL-37 levels were found between patients with bipolar disorder, bacterial pneumonia (p less than 0.001) and pulmonary TB (p=0.004). Our findings suggest that changes observed in the serum level of LL-37 in psychiatric patients enrolled in this study could be a result of homeostatic imbalance.

Citing Articles

LL-37: Structures, Antimicrobial Activity, and Influence on Amyloid-Related Diseases.

Bhattacharjya S, Zhang Z, Ramamoorthy A Biomolecules. 2024; 14(3).

PMID: 38540740 PMC: 10968335. DOI: 10.3390/biom14030320.

Immuno-metabolic profile of patients with psychotic disorders and metabolic syndrome. Results from the FACE-SZ cohort.

Foiselle M, Barbosa S, Godin O, Wu C, Boukouaci W, Andre M Brain Behav Immun Health. 2022; 22:100436.

PMID: 35469211 PMC: 9034311. DOI: 10.1016/j.bbih.2022.100436.

References

Koczulla R, von Degenfeld G, Kupatt C, Krotz F, Zahler S, Gloe T . An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest. 2003; 111(11):1665-72. PMC: 156109. DOI: 10.1172/JCI17545. View

Greer A, Zenobia C, Darveau R . Defensins and LL-37: a review of function in the gingival epithelium. Periodontol 2000. 2013; 63(1):67-79. PMC: 3744237. DOI: 10.1111/prd.12028. View

Nagaoka I, Tamura H, Hirata M . An antimicrobial cathelicidin peptide, human CAP18/LL-37, suppresses neutrophil apoptosis via the activation of formyl-peptide receptor-like 1 and P2X7. J Immunol. 2006; 176(5):3044-52. DOI: 10.4049/jimmunol.176.5.3044. View

Kegeles L, Mao X, Stanford A, Girgis R, Ojeil N, Xu X . Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 2012; 69(5):449-59. DOI: 10.1001/archgenpsychiatry.2011.1519. View

Lee M, Shi X, Barron A, McGeer E, McGeer P . Human antimicrobial peptide LL-37 induces glial-mediated neuroinflammation. Biochem Pharmacol. 2015; 94(2):130-41. DOI: 10.1016/j.bcp.2015.02.003. View

Schaller-Bals S, Schulze A, Bals R . Increased levels of antimicrobial peptides in tracheal aspirates of newborn infants during infection. Am J Respir Crit Care Med. 2002; 165(7):992-5. DOI: 10.1164/ajrccm.165.7.200110-020. View

Nozaki S, Kato M, Takano H, Ito H, Takahashi H, Arakawa R . Regional dopamine synthesis in patients with schizophrenia using L-[beta-11C]DOPA PET. Schizophr Res. 2008; 108(1-3):78-84. DOI: 10.1016/j.schres.2008.11.006. View

Stryjewski M, Hall R, Chu V, Kanafani Z, ORiordan W, Weinstock M . Expression of antimicrobial peptides in the normal and involved skin of patients with infective cellulitis. J Infect Dis. 2007; 196(9):1425-30. DOI: 10.1086/522630. View

Nagaoka I, Suzuki K, Niyonsaba F, Tamura H, Hirata M . Modulation of neutrophil apoptosis by antimicrobial peptides. ISRN Microbiol. 2013; 2012:345791. PMC: 3658579. DOI: 10.5402/2012/345791. View

10.

Monji A, Kato T, Mizoguchi Y, Horikawa H, Seki Y, Kasai M . Neuroinflammation in schizophrenia especially focused on the role of microglia. Prog Neuropsychopharmacol Biol Psychiatry. 2011; 42:115-21. DOI: 10.1016/j.pnpbp.2011.12.002. View

11.

Kahlenberg J, Kaplan M . Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease. J Immunol. 2013; 191(10):4895-901. PMC: 3836506. DOI: 10.4049/jimmunol.1302005. View

12.

Muneer A . Bipolar Disorder: Role of Inflammation and the Development of Disease Biomarkers. Psychiatry Investig. 2016; 13(1):18-33. PMC: 4701682. DOI: 10.4306/pi.2016.13.1.18. View

13.

Turkoglu O, Emingil G, Kutukculer N, Atilla G . Gingival crevicular fluid levels of cathelicidin LL-37 and interleukin-18 in patients with chronic periodontitis. J Periodontol. 2009; 80(6):969-76. DOI: 10.1902/jop.2009.080532. View

14.

Scott A, Weldon S, Buchanan P, Schock B, Ernst R, McAuley D . Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo. PLoS One. 2011; 6(10):e26525. PMC: 3196584. DOI: 10.1371/journal.pone.0026525. View

15.

Kozlowska E, Wysokinski A, Brzezinska-Blaszczyk E . Serum levels of peptide cathelicidin LL-37 in elderly patients with depression. Psychiatry Res. 2017; 255:156-160. DOI: 10.1016/j.psychres.2017.05.036. View

16.

Chen X, Li C, Smith R, Xiao Z, Wang J . Differential sensory gating functions between smokers and non-smokers among drug-naive first episode schizophrenic patients. Psychiatry Res. 2011; 188(3):327-33. DOI: 10.1016/j.psychres.2010.12.009. View

17.

Burnet P, Eastwood S, Harrison P . 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology. 1996; 15(5):442-55. DOI: 10.1016/S0893-133X(96)00053-X. View

18.

Egerton A, Chaddock C, Winton-Brown T, Bloomfield M, Bhattacharyya S, Allen P . Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort. Biol Psychiatry. 2013; 74(2):106-12. DOI: 10.1016/j.biopsych.2012.11.017. View

19.

Majewski K, Zelechowska P, Brzezinska-Blaszczyk E . Circulating cathelicidin LL-37 in adult patients with pulmonary infectious diseases. Clin Invest Med. 2017; 40(1):E34-E39. DOI: 10.25011/cim.v40i1.28052. View

20.

Mansour S, Pena O, Hancock R . Host defense peptides: front-line immunomodulators. Trends Immunol. 2014; 35(9):443-50. DOI: 10.1016/j.it.2014.07.004. View